Trial reportThe Journal of allergy and clinical immunology2010
Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients.
Trial report in The Journal of allergy and clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Meta-analysis of microarray data to identify potential signature genes and MiRNAs associated with the pathogenesis of asthma.Journal of translational medicine · 2025Pooled it
- Genome-wide association study in minority children with asthma implicates DNAH5 in bronchodilator responsiveness.Scientific reports · 2022Pooled it
- A meta-analysis of genome-wide association studies for serum total IgE in diverse study populations.The Journal of allergy and clinical immunology · 2013Pooled it
- Bioinformatics identification of ferroptosis-related genes and therapeutic drugs in rheumatoid arthritis.Frontiers in medicine · 2023Article
- Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy.Pharmacogenomics and personalized medicine · 2020Review
- Emerging Regulatory Roles of Dual-Specificity Phosphatases in Inflammatory Airway Disease.International journal of molecular sciences · 2019Review
- How does race and ethnicity effect the precision treatment of asthma?Expert review of precision medicine and drug development · 2019Article
- Genome-Wide Posttranscriptional Dysregulation by MicroRNAs in Human Asthma as Revealed by Frac-seq.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review.The Journal of international medical research · 2017Review
- CMTR1 is associated with increased asthma exacerbations in patients taking inhaled corticosteroids.Immunity, inflammation and disease · 2015Article
- Is personalized medicine achievable in obstetrics?Seminars in perinatology · 2014Review
- A steroid-mimicking nanomaterial that mediates inhibition of human lung mast cell responses.Nanomedicine : nanotechnology, biology, and medicine · 2014Article
- Inhaled corticosteroid treatment modulates ZNF432 gene variant's effect on bronchodilator response in asthmatics.The Journal of allergy and clinical immunology · 2014Article
- Article
- Spinal cannabinoid receptor type 2 agonist reduces mechanical allodynia and induces mitogen-activated protein kinase phosphatases in a rat model of neuropathic pain.The journal of pain · 2012Article
- Integrative systems biology approaches in asthma pharmacogenomics.Pharmacogenomics · 2012Review
- Corticosteroids and β₂-agonists upregulate mitogen-activated protein kinase phosphatase 1: in vitro mechanisms.British journal of pharmacology · 2012Article
- Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence.The Journal of allergy and clinical immunology · 2011Article
- The pharmacogenetics and pharmacogenomics of asthma therapy.The pharmacogenomics journal · 2011Review
- Advances in pediatric asthma in 2010: addressing the major issues.The Journal of allergy and clinical immunology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 11 institutions in 3 countries.
Funding
Abstract
backgroundInhaled corticosteroids (ICSs) are considered first-line treatment for persistent asthma, yet there is significant variability in treatment response. Dual-specificity phosphatase 1 (DUSP1) appears to mediate the anti-inflammatory action of corticosteroids.
objectiveWe sought to determine whether variants in the DUSP1 gene are associated with clinical response to ICS treatment.
methodsStudy participants with asthma were drawn from the following multiethnic cohorts: the Genetics of Asthma in Latino Americans (GALA) study; the Study of African Americans, Asthma, Genes & Environments (SAGE); and the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE). We screened GALA study participants for genetic variants that modified the relationship between ICS use and bronchodilator response. We then replicated our findings in SAGE and SAPPHIRE participants. In a group of SAPPHIRE participants treated with ICSs for 6 weeks, we examined whether a DUSP1 polymorphism was associated with changes in FEV(1) and self-reported asthma control.
resultsThe DUSP1 polymorphisms rs881152 and rs34507926 localized to different haplotype blocks and appeared to significantly modify the relationship between ICS use and bronchodilator response among GALA study participants. This interaction was also seen for rs881152 among SAPPHIRE but not SAGE participants. Among the group of SAPPHIRE participants prospectively treated with ICSs for 6 weeks, rs881152 genotype was significantly associated with changes in self-reported asthma control but not FEV(1).
conclusionDUSP1 polymorphisms were associated with clinical response to ICS therapy and therefore might be useful in the future to identify asthmatic patients more likely to respond to this controller treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.